Key Takeaways from the FDA’s First Draft Guidance on Clinical Trials with Psychedelic Drugs
Key Takeaways from the FDA’s First Draft Guidance on Clinical Trials with Psychedelic Drugs
On June 26, 2023, the U.S. Food and Drug Administration (FDA) issued its first draft guidance entitled Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry (Guidance), which highlights considerations for sponsors developing psychedelic drugs for treatment of medical conditions (e.g., psychiatric disorders, substance use disorders) and for clinical trials that will be conducted under an investigational […]
Go to Source
Powered by WPeMatico